125 related articles for article (PubMed ID: 1619019)
21. [Treatment of macroprolactinomas with delayed bromocriptine. Effectiveness of a single intramuscular injection].
García-Luna PP; Leal-Cerro A; Pereira JL; Navarro E; Trujillo F; Cortés A; Villamil F; Acosta D; Santos C; Revuelta M
Med Clin (Barc); 1990 Feb; 94(4):126-9. PubMed ID: 2325463
[TBL] [Abstract][Full Text] [Related]
22. [Immediate efficacy of bromocriptine (BrC)-LAR in the treatment of macroprolactinomas: apropos of a case].
García Calzado MC; Ruiz Buendía A
Rev Clin Esp; 1992 Jun; 191(2):112-3. PubMed ID: 1502384
[No Abstract] [Full Text] [Related]
23. Efficacy and tolerability of a long-acting intramuscularly injectable depot preparation of bromocriptine: the results of a double blind study.
Schulz A; Lancranjan I; Schürmeyer T; Schuppert F; Hesch RD; von zur Mühlen A; Brabant G
J Endocrinol Invest; 1991 Jun; 14(6):469-74. PubMed ID: 1774443
[TBL] [Abstract][Full Text] [Related]
24. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
Ciccarelli E; Ghigo E; Mazza E; Andreis M; Massara F; Lancranjan I; Camanni F
J Endocrinol Invest; 1987 Apr; 10(2):179-82. PubMed ID: 3584856
[TBL] [Abstract][Full Text] [Related]
25. Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics.
Espinós JJ; Rodríguez-Espinosa J; Webb SM; Calaf-Alsina J
Fertil Steril; 1994 Nov; 62(5):926-31. PubMed ID: 7926136
[TBL] [Abstract][Full Text] [Related]
26. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
27. Long-acting bromocriptine for the acute treatment of large macroprolactinomas.
Zarate A; Moran C; Miranda R; Loyo M; Medina M; Fonseca ME
J Endocrinol Invest; 1987 Jun; 10(3):233-6. PubMed ID: 3624799
[TBL] [Abstract][Full Text] [Related]
28. The efficacy, tolerability and safety of Parlodel LAR versus Parlodel in hyperprolactinemia.
Bolanowski M; Milewicz A; Bohdanowicz-Pawlak A; Bednarek-Tupikowska G; Jedrzejak JA; Lancranjan I
Endokrynol Pol; 1993; 44(4):467-76. PubMed ID: 8055815
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
30. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
32. Mixed pituitary tumours--effects of bromocriptine treatment: Parlodel MR and Parlodel LAR.
Zgliczyński W; Zgliczyński S; Makowska A; Słowinska-Srzednicka J; Janik J; Jeske W; Walecki J
Endokrynol Pol; 1992; 43(3):242-9. PubMed ID: 1345565
[TBL] [Abstract][Full Text] [Related]
33. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
35. [Parenteral, depot and repeatable forms of Parlodel LAR bromocriptine in the treatment of hyperprolactinemia syndrome. Comparison with oral Parlodel].
Dolecek R; Lancranjanová I; Putz Z; Vavros D; Závada M
Cas Lek Cesk; 1993 Feb; 132(3):81-5. PubMed ID: 8458069
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.
Pagani MD; Tengattini F; Montini M; Pagani G; Pedroncelli A; Gianola D; Gherardi F; Mazzocchi N; Cortesi L; Lancranjan I
Clin Endocrinol (Oxf); 1992 Apr; 36(4):369-74. PubMed ID: 1424170
[TBL] [Abstract][Full Text] [Related]
37. Effect of injectable bromocriptine in patients with Cushing's disease.
Invitti C; De Martin M; Danesi L; Cavagnini F
Exp Clin Endocrinol Diabetes; 1995; 103(4):266-71. PubMed ID: 7584534
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas.
Essaïs O; Bouguerra R; Hamzaoui J; Marrakchi Z; Hadjri S; Chamakhi S; Zidi B; Ben Slama C
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):524-31. PubMed ID: 12527854
[TBL] [Abstract][Full Text] [Related]
39. Short-term management of macroprolactinomas with a new injectable form of bromocriptine.
Bronstein MD; Cardim CS; Marino R
Surg Neurol; 1987 Jul; 28(1):31-7. PubMed ID: 3589939
[TBL] [Abstract][Full Text] [Related]
40. [Bromocriptine for macroprolactinomas. Discussion of 3 cases treated successfully].
Sapunar J; López JM; Huete I; Tagle R
Rev Med Chil; 1992 Feb; 120(2):168-73. PubMed ID: 1340555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
